Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Punit Saraon, Shivanthy Pathmanathan, Jamie Snider, et al.
Oncogene (2021) Vol. 40, Iss. 24, pp. 4079-4093
Closed Access | Times Cited: 133

Showing 1-25 of 133 citing articles:

Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma
Yahaya A Yabo, Simone P. Niclou, Anna Golebiewska
Neuro-Oncology (2021) Vol. 24, Iss. 5, pp. 669-682
Open Access | Times Cited: 170
Targeted therapy for osteosarcoma: a review
Shizhe Li, He Zhang, Jinxin Liu, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 9, pp. 6785-6797
Closed Access | Times Cited: 46
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Ali Doostmohammadi, Hossein Jooya, Kimia Ghorbanian, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 34
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Ciprian Tomuleasa, Adrian Bogdan Țigu, Raluca Munteanu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Rational Design, Synthesis, and Biological Evaluation of Novel c-Met Degraders for Lung Cancer Therapy
Xingyang Qiu, Qingquan Zheng, Dongdong Luo, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Clinical considerations for the design of PROTACs in cancer
Cristina Nieto‐Jiménez, Esther Cabañas Morafraile, Carlos Alonso‐Moreno, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 62
Computer-aided drug design in anti-cancer drug discovery: What have we learnt and what is the way forward?
Opeyemi Iwaloye, Paul Olamide Ottu, Femi Olawale, et al.
Informatics in Medicine Unlocked (2023) Vol. 41, pp. 101332-101332
Open Access | Times Cited: 39
EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
Xiaoping He, Yohko Hikiba, Yoshimasa Suzuki, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 38
Receptor-Targeted Nanomedicine for Cancer Therapy
Arvee Prajapati, Shagun Rangra, Rashmi Patil, et al.
Receptors (2024) Vol. 3, Iss. 3, pp. 323-361
Open Access | Times Cited: 12
Design and Synthesis of New Dihydropyrimidine Derivatives with a Cytotoxic Effect as Dual EGFR/VEGFR-2 Inhibitors
Lamya H. Al-Wahaibi, Ali M. Elshamsy, Taha F. S. Ali, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34358-34369
Open Access | Times Cited: 11
Cheminformatics-based identification of phosphorylated RET tyrosine kinase inhibitors for human cancer
Md. Enamul Kabir Talukder, Md. Aktaruzzaman, Noimul Hasan Siddiquee, et al.
Frontiers in Chemistry (2024) Vol. 12
Open Access | Times Cited: 10
Structure–Activity Relationship Study and Design Strategies of Hydantoin, Thiazolidinedione, and Rhodanine-Based Kinase Inhibitors: A Two-Decade Review
Muhammad Naufal, Elvira Hermawati, Yana Maolana Syah, et al.
ACS Omega (2024) Vol. 9, Iss. 4, pp. 4186-4209
Open Access | Times Cited: 8
The Role of αvβ3 Integrin in Cancer Therapy Resistance
Bianca Cruz Pachane, Heloísa Sobreiro Selistre-de-Araújo
Biomedicines (2024) Vol. 12, Iss. 6, pp. 1163-1163
Open Access | Times Cited: 8
Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade
Minjie Fu, Jiaxu Zhao, Licheng Zhang, et al.
Cancer Cell (2024) Vol. 42, Iss. 11, pp. 1882-1897.e7
Closed Access | Times Cited: 8
An Alternative Mode of GPCR Transactivation: Activation of GPCRs by Adhesion GPCRs
Hsi‐Hsien Lin
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 552-552
Open Access | Times Cited: 1
Pyrimidine scaffold dual‐target kinase inhibitors for cancer diseases: A review on design strategies, synthetic approaches, and structure–activity relationship (2018‒2023)
Minseok Song, Ahmed Elkamhawy, Woojeong Noh, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 1
Closed Access | Times Cited: 1
Attenuated growth factor signaling during cell death initiation sensitizes membranes towards peroxidation
André Gollowitzer, Helmut Pein, Zhigang Rao, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages
Mingxuan Zhu, Liangliang Bai, Xiaoxia Liu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005610-e005610
Open Access | Times Cited: 34
Synthesis of novel pyrido[2,3-d]pyrimidine-thiazolidine-1,2,3-triazoles: Potent EGFR targeting anticancer agents
Sandhya Rani Bandi, Ravikumar Kapavarapu, Rambabu Palabindela, et al.
Journal of Molecular Structure (2023) Vol. 1294, pp. 136451-136451
Closed Access | Times Cited: 20
Novel quinazoline-1,2,3-triazole hybrids with anticancer and MET kinase targeting properties
Motahareh Mortazavi, Masoomeh Eskandari, Fatemeh Moosavi, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 17
Sensational site: the sodium pump ouabain-binding site and its ligands
Mordecai P. Blaustein, John M. Hamlyn
AJP Cell Physiology (2024) Vol. 326, Iss. 4, pp. C1120-C1177
Open Access | Times Cited: 7
Molecular basis of VEGFR1 autoinhibition at the plasma membrane
Manas Pratim Chakraborty, Diptatanu Das, Purav Mondal, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity
Carmine Rocca, Ernestina Marianna De Francesco, Teresa Pasqua, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 520-520
Open Access | Times Cited: 26
Design and synthesis of new 2-oxoquinoxalinyl-1,2,4-triazoles as antitumor VEGFR-2 inhibitors
Merve Zengin, Oya Ünsal Tan, Reem K. Arafa, et al.
Bioorganic Chemistry (2022) Vol. 121, pp. 105696-105696
Closed Access | Times Cited: 23
Ectopic biomolecular phase transitions: fusion proteins in cancer pathologies
Richoo B. Davis, Mahdi Muhammad Moosa, Priya R. Banerjee
Trends in Cell Biology (2022) Vol. 32, Iss. 8, pp. 681-695
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top